cell-based assays | GenomeWeb

cell-based assays

Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.

Fluidigm Polaris

At AGBT, Fluidigm showcased the Polaris system for integrated single-cell analysis and new applications for the C1, including high-throughput RNA-seq and protein analysis.

NEW YORK (GenomeWeb) – Japanese stem cell products company Reprocell said today that it has purchased 3D cell culture firm Reinnervate and US genomics services firm BioServe.

Exagen Raises $3.95M

NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.

NEW YORK (GenomeWeb) – Lophius Biosciences today announced it received a €2.0 million ($2.8 million) investment to fund clinical studies of its flagship product and to develop new products.
The firm also announced a new CEO and changes to its board.

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Symcel this week introduced a new platform called calScreener that can provide real-time cellular bioenergetic measurements of 32 samples at a time.

NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a collaboration with Axxam to offer integrated discovery services based on genomic engineering technologies.


In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.